spruce bioscience - TA-ERT breakthrough designatio
Post# of 157749
(Total Views: 334)
Posted On: 10/07/2025 11:42:41 AM
spruce bioscience - TA-ERT breakthrough designation -
april 2025 upon acquiring TA-ERT from bankrupt Allievex - "Spruce has secured the chance to seek accelerated approval on the strength of existing data"
so is this how it works? Allievex had the goods - but simply (or not so simply) couldnt afford to move forward with a drug that they had ample evidence that it was worthy of approval, goes bankrupt in the process, and the next company reaps the reward with no further data? where were the next round of investors? why would it be so hard for them to raise funds? need to investigate this more, what am i missing?
also, with so few worldwide patients, the patient cost must be astronomical. similar therapies $300k / yr and im not sure how these drugs for rare diseases can command such a high pricetag and who really gets to set this number. ...i recall the $1200 / 1400 (is this still the assume cost if ever approved?) per dose for leronlimab causing an uproar with the detractors during covid days. to, you know, save your life and stuff.
what am i missing?
clearly cytodyn is in a much stronger position by a mile as of today than allievex, and yes a BTD would accelerate stock price IMO.
april 2025 -
https://www.fiercebiotech.com/biotech/spruce-...val-filing
april 2025 upon acquiring TA-ERT from bankrupt Allievex - "Spruce has secured the chance to seek accelerated approval on the strength of existing data"
so is this how it works? Allievex had the goods - but simply (or not so simply) couldnt afford to move forward with a drug that they had ample evidence that it was worthy of approval, goes bankrupt in the process, and the next company reaps the reward with no further data? where were the next round of investors? why would it be so hard for them to raise funds? need to investigate this more, what am i missing?
also, with so few worldwide patients, the patient cost must be astronomical. similar therapies $300k / yr and im not sure how these drugs for rare diseases can command such a high pricetag and who really gets to set this number. ...i recall the $1200 / 1400 (is this still the assume cost if ever approved?) per dose for leronlimab causing an uproar with the detractors during covid days. to, you know, save your life and stuff.
what am i missing?
clearly cytodyn is in a much stronger position by a mile as of today than allievex, and yes a BTD would accelerate stock price IMO.
april 2025 -
https://www.fiercebiotech.com/biotech/spruce-...val-filing
Quote:
With only 19,000 potential patients worldwide expect Spruce Bioscience's share price to tumble back down. If Spruce is smart they will use the increased share price to sell some shares and put some money in the bank. Quite unlike a former CEO who was only interested in lining his own pockets.
A BTD for leronlimab is more likely to sustain an increased share price. Once investors realize that a BTD for leronlimab based on a combination with a PD-L1 or PD-1 inhibitor would work across multiple cancer types with an exponentially large market there would be quite a bit of excitement. A BTD for Alzheimer's would be even bigger. In either case there would be a price spike and rollback as there always is when FOMO is involved but the share price would remain relatively high.
(3)
(0)